REPRODUCTIVE HORMONES & THE FERTILITY AXIS / COLOPHON
About This Primer
A citation-anchored primer on the reproductive-peptide literature. Nothing sold here, no clinic, no medical advice.
What the primer covers
Aubrie Peptides is a plain-language primer on the published research behind two peptides studied for reproductive hormones and the fertility axis: kisspeptin and PT-141 (bremelanotide), with kisspeptin as the lead. The aim is to make a technically demanding, clinically complex, and frequently misrepresented literature legible — to tell a reader, in plain language and with citations, what each compound was actually studied for, in which populations, and how far that evidence reaches.
The organizing idea is the fertility axis, plainly explained. Kisspeptin acts upstream on the HPG axis — the body's hormonal pulse generator. PT-141 acts downstream, in the neural circuits of desire. Together they cover the biology of sexual and reproductive health from two complementary angles. Each compound has its own page, a comparison page sets them together, and a single shared references list gathers every source.
The topics here — libido, arousal, reproductive hormones, sexual desire — are handled frankly and with the depth the research deserves. Community-reported effects appear, marked clearly as anecdotal and not clinical evidence, because they belong to the honest picture. What the primer never does is recommend, prescribe, suggest a dose, or imply that any compound here suits self-administration.
How the primer is written
Every claim on the site keys to a specific, numbered citation in the shared references list. Sources were drawn from peer-reviewed journals (PubMed-indexed), systematic reviews, and official regulatory documents (prescribing information) — no secondary sources, no press releases, no vendor claims. A preclinical finding (animal or cell data) is named as such, alongside the species and model. Where human data exist, the study design, population, and sample size are noted, because a Phase 2 study of 60 women and a Phase 3 program of 1,267 women support very different confidence.
The full index is reproduced on the references page, with DOI and PubMed links, and every cited number in the text maps to it. Where the evidence is thin, preliminary, contested, or not yet replicated at scale, the primer says so — as part of the record, not as a closing disclaimer. Where community anecdote is included (real-world reported effects), it is kept apart from study-attributed findings and identified plainly as anecdotal, not clinical evidence.
No author biographies, credentials, or affiliations are fabricated here. This is an editorial primer; its standard is the accuracy and completeness of its citation trail.
The boundaries
Aubrie Peptides is not a vendor, not a pharmacy, and not a clinic. It sells no compounds, recommends no suppliers, and gives no medical advice. It lists no human doses. It never suggests that any compound here suits self-administration outside a supervised research or medical setting.
The compounds vary widely in regulatory and safety profile: PT-141 (bremelanotide) is a prescription-only pharmaceutical in its approved indication [12]; kisspeptin is wholly investigational, with no approved indication [2]. Neither that fact nor any content here is a medical recommendation. A reader with clinical questions about reproductive health, low sexual desire, fertility, or hormonal conditions should consult a licensed healthcare provider — not a primer.
Contact: editorial@aubriepeptides.com